Nonalcoholic steatohepatitis (NASH) drugs market (original) (raw)

• From the Analyst's Couch
• Published: 03 November 2016

Nature Reviews Drug Discovery volume 15, pages 745–746 (2016)Cite this article

• 6491 Accesses
• 62 Citations
• 20 Altmetric
• Metrics details

Subjects

Current treatments

At present, there are no approved therapies for NASH. Currently, diagnosis is dependent on liver biopsy evaluation, with treatment aiming to control the medical conditions associated with the disease, such as obesity, T2DM and hyperlipidaemia.

Author information

Authors and Affiliations

1. Sorcha Cassidy and Basharut A. Syed are at FirstWord Pharma, PSL Group, 75 Davies Street, London W1K 5JN, UK.,
   Sorcha Cassidy & Basharut A. Syed

Authors

1. Sorcha Cassidy
2. Basharut A. Syed

Corresponding author

Correspondence toBasharut A. Syed.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

About this article

Cite this article

Cassidy, S., Syed, B. Nonalcoholic steatohepatitis (NASH) drugs market.Nat Rev Drug Discov 15, 745–746 (2016). https://doi.org/10.1038/nrd.2016.188

Download citation

• Published: 03 November 2016
• Issue date: November 2016
• DOI: https://doi.org/10.1038/nrd.2016.188

This article is cited by